Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia

Asia-Pacific Journal of Clinical Oncology

Volumn 6, Issue 3, 2010, Pages 155-160

  Chalermchai, T ^a   Tantiphlachiva, K ^b   Suwanrusme, H ^a   Voravud, N ^a   Sriuranpong, V ^a  

^a Department of Medicine   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Capecitabine; Palmar plantar erythrodysesthesia; Pyridoxine

Indexed keywords

CAPECITABINE; PYRIDOXINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHEMA; FEMALE; FLUOROURACIL; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; MALE; MIDDLE AGED; PYRIDOXINE; VITAMIN B COMPLEX;

EID: 77956297628     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2010.01311.x     Document Type: Article

References (22)

1. Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984, 101:798-9.
2. Amantea M, Newman MS, Sullivan TM, Forrest A, Working PK. Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 1999, 18:17-26.
3. Banfield GK, Crate ID, Griffiths CL. Long-term sequelae of palmar-plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy. J R Soc Med 1995, 88:356P-357P.
4. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995, 75:2169-73.
5. Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 1974, 148:90-2.
6. Komamura H, Higashiyama M, Hashimoto K. Three cases of chemotherapy-induced acral erythema. J Dermatol 1995, 22:116-21.
7. Burgdorf WH, Gilmore WA, Ganick RG. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med 1982, 97:61-2.
8. Zimmerman GC, Keeling JH, Burris HA. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995, 131:202-6.
9. Calista D, Landi C. Cytarabine-induced acral erythema: a localized form of toxic epidermal necrolysis? J Eur Acad Dermatol Venereol 1998, 10:274-5.
10. Azurdia RM, Clark RE, Friedmann PS. Chemotherapy-induced acral erythema (CIAE) with bullous reaction. Clin Exp Dermatol 1999, 24:64-6.
11. Chiara S, Nobile MT, Barzacchi C. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer 1997, 33:967-9.
12. Van Cutsem E, Twelves C, Cassidy J. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001, 19:4097-106.
13. Blum JL, Dieras V, Lo Russo PM. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001, 92:1759-68.
14. Twelves C, Wong A, Nowacki MP. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352:2696-704.
15. Hoff PM, Ansari R, Batist G. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001, 19:2282-92.
16. Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999, 44:303-6.
17. Olver IN, Aisner J, Hament A, Buchanan L, Bishop JF, Kaplan RS. A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 1988, 6:1732-5.
18. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 2002, 16:31-7.
19. Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990, 8:57-63.
20. Lauman MK, Mortimer J. Effect of pyridoxine on the incidence of palmar plantar erythroderma (PPE) in patients receiving capecitabine. Proc Am Soc Clin Oncol 2001, 20. abstr 1565
21. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998, 4:1567-71.
22. Wiernik PH, Yeap B, Vogl SE. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest 1992, 10:1-9.